The benefits of combined treatment with corticosteroids and longacting beta agonists
International Journal of COPD · 2006
DOI: 10.2147/copd.2006.1.3.207 ↗At a glance
Editorial in International Journal of COPD, 2006. Written by Dave Singh. Major MEDLINE topics: Delayed-Action Preparations, Drug Therapy, Combination. 10 references. The full text is freely available in PubMed Central.
Abstract (original language)
The benefits of combined treatment with corticosteroids and longacting beta agonistsGuidelines for the treatment of COPD recommend that long-acting beta agonists (LABA) are used initially to maximize lung function and relieve symptoms in patients with mild to moderate disease who are being treated with short-acting bronchodilators (www.goldcopd.com).Inhaled corticosteroid (ICS) therapy reduces exacerbation rates in patients with more severe disease (Burge et al 2000), and so guidelines recommend that these drugs are used for this purpose primarily in patients with FEV 1
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Singh, D. (2006). The benefits of combined treatment with corticosteroids and longacting beta agonists. International Journal of COPD. https://doi.org/10.2147/copd.2006.1.3.207
Vancouver
Singh D. The benefits of combined treatment with corticosteroids and longacting beta agonists. International Journal of COPD. 2006. doi:10.2147/copd.2006.1.3.207
BibTeX
@article{Singh2006,
author = {Singh, Dave},
title = {The benefits of combined treatment with corticosteroids and longacting beta agonists},
journal = {International Journal of COPD},
year = {2006},
doi = {10.2147/copd.2006.1.3.207}
}
EUVIMED